Barclays’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-12,600
| Closed | -$43K | – | 7693 |
|
|
2018
Q3 | $43K | Buy |
12,600
+1,900
| +18% | +$6.85K | ﹤0.01% | 6169 |
|
|
2018
Q2 | $40K | Sell |
10,700
-5,500
| -34% | -$26.8K | ﹤0.01% | 5783 |
|
|
2018
Q1 | $66K | Sell |
16,200
-6,400
| -28% | -$29.8K | ﹤0.01% | 5679 |
|
|
2017
Q4 | $105K | Buy |
22,600
+9,300
| +70% | +$51.2K | ﹤0.01% | 5204 |
|
|
2017
Q3 | $94K | Sell |
13,300
-13,900
| -51% | -$99.9K | ﹤0.01% | 4979 |
|
|
2017
Q2 | $197K | Buy |
27,200
+16,400
| +152% | +$102K | ﹤0.01% | 4372 |
|
|
2017
Q1 | $67K | Sell |
10,800
-8,000
| -43% | -$43.8K | ﹤0.01% | 5165 |
|
|
2016
Q4 | $110K | Sell |
18,800
-15,100
| -45% | -$82.5K | ﹤0.01% | 4683 |
|
|
2016
Q3 | $180K | Buy |
33,900
+13,300
| +65% | +$71.7K | ﹤0.01% | 4046 |
|
|
2016
Q2 | $136K | Buy |
20,600
+16,600
| +415% | +$92.8K | ﹤0.01% | 4194 |
|
|
2016
Q1 | $16K | Sell |
4,000
-7,100
| -64% | -$28.3K | ﹤0.01% | 5321 |
|
|
2015
Q4 | $56K | Sell |
11,100
-28,200
| -72% | -$134K | ﹤0.01% | 4734 |
|
|
2015
Q3 | $118K | Sell |
39,300
-99,300
| -72% | -$665K | ﹤0.01% | 4514 |
|
|
2015
Q2 | $1.25M | Buy |
138,600
+110,100
| +386% | +$1.18M | ﹤0.01% | 2686 |
|
|
2015
Q1 | $342K | Sell |
28,500
-134,200
| -82% | -$1.73M | ﹤0.01% | 3931 |
|
|
2014
Q4 | $2.28M | Sell |
162,700
-41,200
| -20% | -$638K | ﹤0.01% | 2411 |
|
|
2014
Q3 | $2.65M | Buy |
203,900
+47,200
| +30% | +$723K | ﹤0.01% | 2402 |
|
|
2014
Q2 | $2.35M | Buy |
156,700
+135,600
| +643% | +$1.92M | ﹤0.01% | 2429 |
|
|
2014
Q1 | $359K | Sell |
21,100
-136,200
| -87% | -$2.05M | ﹤0.01% | 4230 |
|
|
2013
Q4 | $1.89M | Sell |
157,300
-57,800
| -27% | -$690K | ﹤0.01% | 2734 |
|
|
2013
Q3 | $2.15M | Buy |
215,100
+129,500
| +151% | +$1.15M | ﹤0.01% | 2483 |
|
|
2013
Q2 | $639K | Buy |
+85,600
| New | +$669K | ﹤0.01% | 3926 |
|
Barclays's KERX Position: Q4 2018 in Review
Barclays sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 259,160 shares — an estimated $881K sold.
Barclays first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $970K in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Barclays reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Barclays sold 259,160 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $881K.
- Barclays first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Barclays's Keryx Biopharmaceuticals Inc position peaked at $970K in Q3 2017.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.